Global rubella diagnostic testing market set to grow to $2.23 billion by 2033

From GlobeNewswire: 2024-06-24 16:00:00

The Global Rubella Diagnostic Testing Market is set to grow from $1.35 billion in 2023 to $2.23 billion by 2033, with a CAGR of 5.15%. Rubella diagnostic testing detects antibodies to the rubella virus, causing a highly contagious infection known as German measles. Infectious, it can be spread through coughing or sneezing. Market growth is driven by outbreaks, advanced testing methods, and declining vaccination rates.

Enzyme immunoassay (EIA) accounts for the largest share in the rubella diagnostic testing market. EIA reagents are widely used for antigen detection in epidemiological outbreaks and are commonly used for IgM testing. Hospitals are projected to see the fastest growth due to the adoption of rapid testing technologies. North America is expected to dominate the market, with the US seeing fewer cases of rubella each year. Asia Pacific is anticipated to grow rapidly due to increased diagnostic facilities.

Recent developments in the rubella diagnostic testing market include the formation of the Measles & Rubella Partnership by key organizations to meet vaccination targets. Market segmentation is based on testing techniques like latex agglutination, EIA, RIA, FIA, and applications such as hospitals, laboratories, and others. The report provides detailed analysis of key players, market shares, and competitive landscape. For more information, contact Spherical Insights & Consulting.



Read more at GlobeNewswire: Global Rubella Diagnostic Testing Market Size To Worth USD